GENETIKA+ enters into a multiphasic collaboration with NeuroSense for its ongoing P-II study in patients with Alzheimer’s in this Genetika will use its technology to quantify neuronal plasticity from frontal cortex neurons derived from patient’s blood
NeuroSense’s PrimeC therapy addresses multiple disease related pathologies like Aβ aggregation and TDP-43 simultaneously making it different, unique, more potent approach for treatment outcomes from conventional method that just targets amyloid-beta (Aβ)
Currently enrolling at the Stroke and Cognition Institute (Israel) for P-II (RoAD) trial, to evaluate safety & efficacy of PrimeC for the treatment AD. Study will enrol mild to moderate non-familial AD (n=20) to receive PrimeC vs. PBO (1:1) BID for 12 mos. to be assessed at every 3mos.
Ref: GENETIKA | Image: GENETIKA
Related News:- NeuroSense and Lonza Partner to Explore Exosome-based Biomarkers for the Diagnosis and Treatment of Neurodegenerative Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
